ACLY and metabolic disease: So, ACLY is considered an anti-cancer drug target with a great therapeutic potential [20, 23, 24], and there is a great effort to develop new ACLY inhibitors or to re-evaluate those previously developed for metabolic disorders [20, 25–27].